Opportunities for Investors: Join the Ultragenyx Class Action
In a pivotal moment for shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), it has been reported that individuals who significantly lost in investments have a unique opportunity to lead a class action lawsuit. This process is guided by Robbins Geller Rudman & Dowd LLP, a leading class action firm, to ensure that investor rights are enforced and that justice is sought for the financial losses incurred.
Understanding the Class Action Lawsuit
The class action, officially titled Bailey v. Ultragenyx Pharmaceutical Inc., bears the case number No. 26-cv-01097 (N.D. Cal.). This lawsuit focuses on allegations that Ultragenyx and high-ranking executives misrepresented key information, resulting in substantial investor losses. The period of concern stretches from August 3, 2023, to December 26, 2025, covering crucial developments within the company that may have misled shareholders.
Key Allegations Against Ultragenyx
According to the class action complaint, Ultragenyx is accused of making erroneous statements and failing to disclose vital information regarding their development of setrusumab for Osteogenesis Imperfecta (OI). During the class period, the firm allegedly gave the impression that they possessed reliable data on the treatment's effects while downplaying serious risks involved in clinical trials, particularly the Phase III Orbit study. Investors were led to believe that favorable results were imminent despite underlying doubts about the study's integrity.
The Recent Developments and Their Impact
On July 9, 2025, Ultragenyx's stock price saw a staggering drop when the company announced that their Phase III Orbit study did not meet the necessary statistical significance for the second interim analysis. This revelation came as a shock to investors who had placed confidence in Ultragenyx's optimistic statements. Subsequently, the stock plummeted more than 25% due to this failing news, leading many investors to experience considerable financial hardship.
Further Setbacks for Investors
Following this, another blow struck on December 29, 2025, when Ultragenyx publicly stated that both the Phase III Orbit and Cosmic Studies had not met their primary endpoints, further eroding investor trust. The reaction was swift, with shares experiencing a dramatic decrease of over 42% in valuation. These developments have painted a troubling picture for the company, highlighting the significant risks and miscommunications that have occurred.
The Role of the Lead Plaintiff
The process for becoming a lead plaintiff in the Ultragenyx class action is part of the provisions afforded by the Private Securities Litigation Reform Act of 1995. Interested investors who purchased shares during the class period have the chance to step forward for this role. A lead plaintiff serves to represent the collective interests of all investors involved, working to guide the legal proceedings and advocate for potential recoveries.
Engaging with Legal Expertise
As a lead plaintiff, an investor is empowered to choose their legal representation, with Robbins Geller Rudman & Dowd LLP ready to assist in this journey. It’s essential to understand that participating as a lead plaintiff is not a requirement for all investors to recover potential losses; one can still share in any recoveries achieved through the lawsuit without this designation.
About Robbins Geller Rudman & Dowd LLP
For over a decade, Robbins Geller has emerged as one of the foremost class action law firms in the world. Specializing in securities fraud and protecting shareholder rights, the firm boasts an impressive track record, recovering billions for clients in recent years. Their expertise positions them uniquely to advocate for those affected by Ultragenyx's recent challenges, ensuring that investor voices are heard loud and clear.
Contact Information
Investors seeking more information or wishing to act in this class action are encouraged to reach out directly. Robbins Geller’s J.C. Sanchez can be contacted at 800-449-4900 for assistance and further inquiries.
Frequently Asked Questions
What is a class action lawsuit?
A class action lawsuit allows a group of people with similar claims to litigate together, improving efficiency and amplifying their voices against a defendant.
Who can be a lead plaintiff?
Any investor who purchased Ultragenyx stock during the class period can seek to be the lead plaintiff, representing the collective interests of the class.
What are the allegations against Ultragenyx?
The allegations concern misleading statements about drug trial results and failures that led to significant financial losses for shareholders.
How do I participate in the class action?
Interested parties should contact Robbins Geller for guidance on the application process to become involved in the lawsuit.
Why should I consider joining this lawsuit?
Joining the lawsuit provides an opportunity for recourse against perceived injustices and losses incurred due to the company's actions, ensuring accountability.
